SINEMET CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
May 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SINEMET CR is an extended-release oral tablet combining levodopa and carbidopa, indicated for Parkinson's disease management. The drug works by increasing dopamine levels in the brain through levodopa conversion, with carbidopa preventing peripheral metabolism. This combination addresses motor symptoms and maintains more stable dopamine levels throughout the day compared to immediate-release formulations.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), team size is likely stable but revenue defense strategies are active.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Started Jul 2004
220 enrolled
Parkinson Disease
Career Relevance
Working on SINEMET CR offers stability in a mature, well-understood therapeutic area but limited growth trajectory. Career development requires focus on operational excellence, managed markets, and defending market share against generics rather than innovation or launch execution.
Brand Manager
Worked on SINEMET CR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.